Brief: Rubius Therapeutics Q4 Loss Per Share $0.56
12/03/2020 11:37
Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR
2019
FINANCIAL RESULTS AND ANNOUNCES STRATEGIC FOCUS ON ONCOLOGY AND
AUTOIMMUNITY
* Q4 LOSS PER SHARE $0.56
* Q4 EARNINGS PER SHARE ESTIMATE $-0.60 -- REFINITIV IBES
DATA
* RUBIUS THERAPEUTICS - COMPANY IS DEPRIORITIZING RTX-134
PROGRAM
FOR TREATMENT OF PHENYLKETONURIA (PKU) AND ITS OTHER RARE
DISEASE PROGRAMS
* CASH RUNWAY WILL BE EXTENDED INTO 2022
Source text for Eikon: ID:nGNX9rKSzg
Further company coverage: RUBY.O
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft